1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Aurobindo Integrates Apotex And Prepares For Sandoz

Firm Says Nothing ‘Extraneous’ Holding Up FTC Nod For Sandoz Deal

 
• By Anju Ghangurde

Aurobindo believes it has “substantially addressed” all requirements for an FTC go-ahead for its acquisition of Sandoz’s US dermatology and generic oral solids businesses. The integration of the acquired Apotex business in Europe is also shaping up.

Destination
Aurobindo Moves Towards FTC Clearance For Sandoz Deal • Source: Shutterstock

Aurobindo Pharma Ltd. has emphasized that things are “moving along positively” towards securing approval from the US Federal Trade Commission (FTC) for its acquisition of Sandoz International GMBH’s US dermatology business and generic US oral solids portfolio. It currently estimates that clearance could potentially come by the end of December this year and if not, by January 2020.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.